ARDX - צמיחת מכירות משנה לשנה (TTM) Ardelyx, Inc.

The year-over-year sales trajectory (TTM) provided by the GURU.Markets system confirms the portfolio diversification of Ardelyx, Inc. (ARDX) within the nephrology and gastroenterology sectors, and the value of 17.50 reflects this status. The lifelong nature of therapy for renal pathologies guarantees the company multi-year protected income. The current financial position of the business remains stable, ensuring full coverage of all operating expenses and capital expenditures.
פילוחי נתונים אנליטיים מרוכזים עבור Ardelyx (ARDX)

For Ardelyx, Inc. (ARDX), the year-over-year dynamics of core revenue over a rolling 12-month period serve as an indicator of scaling prescription sales for kidney drugs amid regulatory insurance risks. This metric calculates the percentage deviation of current total sales from the same window of the previous year, converting discrete reports into a continuous trend to assess the sustainability of the operating model and the pace of business expansion.